Damora Therapeutics (DMRA) Accounts Payables (2019 - 2026)

Damora Therapeutics (DMRA) has 8 years of Accounts Payables data on file, last reported at $819000.0 in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables rose 131.36% year-over-year to $819000.0; the trailing twelve-month figure through Mar 2026 stood at $819000.0 (up 131.36% YoY), and the FY2025 full-year result was $444000.0, up 17.77% from the prior year.
• Accounts Payables for Q1 2026 stood at $819000.0, up from $444000.0 in the prior quarter.
• Across five years, Accounts Payables topped out at $5.6 million in Q2 2023 and bottomed at $354000.0 in Q1 2025.
• The 5-year median for Accounts Payables is $1.7 million (2024), against an average of $1.9 million.
• The widest annual swing landed in 2023, when Accounts Payables jumped 134.77%; it then slumped 88.76% in 2024.
• A 5-year view of Accounts Payables shows it stood at $3.4 million in 2022, then plunged by 49.19% to $1.7 million in 2023, then sank by 77.85% to $377000.0 in 2024, then increased by 17.77% to $444000.0 in 2025, then jumped by 84.46% to $819000.0 in 2026.
• The last three Accounts Payables figures came in at $819000.0 (Q1 2026), $444000.0 (Q4 2025), and $520000.0 (Q3 2025), per Business Quant data.

Peer Comparison